Christoph Merten, Professor, Head of the Laboratory for Biomedical Microfluidics

Professor, Head of the Laboratory for Biomedical Microfluidics
EPFL, The Swiss Federal Institute of Technology of Lausanne, Vaud, Switzerland

Christoph A. Merten is a Professor for biomedical microfluidics at the Swiss Federal Institute of Technology (EPFL; www.epfl.ch/labs/lbmm) in Lausanne, Switzerland. He also holds an adjunct position at the Ludwig Institute for Cancer Research (LICR).
In parallel to his academic career, Christoph has gained significant industry and entrepreneurship experience: He successfully commercialized microfluidic technology for genomic applications, collaborated with big pharma (including Roche and GSK) and works as a consultant in the biotech sector. He is also the scientific founder of the antibody discovery company Veraxa Biotech (www.veraxa.de) and leader of the TheraMe! consortium for personalized cancer therapy (www.besttherapyforme.com).
Christoph studied biochemistry and organic chemistry at the University of Frankfurt, where he also received his PhD in 2004 on directed evolution of gene therapy vectors (work carried out at the Paul Ehrlich Institut). He did postdoctoral studies at the MRC Laboratory of Molecular Biology (Cambridge, UK) and the Institute de Science et d’Ingénierie Supramoléculaires (ISIS) in Strasbourg, France. Before moving to Switzerland, he led a group at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany.

Disclosure information not submitted.

Presentation(s):

• Droplet Microfluidics in antibody discovery, immune repertoire sequencing and personalized cancer therapy

  Tuesday, February 8, 2022
  10:30 AM – 11:00 AM